Breaking News Instant updates and real-time market news.

2020-11-24 06:53:15 STN Stantec $29.92 / -0.12 (-0.40%) 06:53 11/24/20 11/24 06:53 11/24/20 06:53	Stantec selected for PDS services for new South Niagara Hospital in Ontario Global design firm, Stantec, was selected to provide planning, design, and conformance, or PDC, services for the new South Niagara Hospital in Niagara Falls, Ontario. Having previously completed the campus plan for Niagara Health, Stantec's healthcare team is now providing the illustrative schematic design, as well as detailed output specifications for the full range of design and construction requirements. Throughout the project duration, Stantec will evaluate conformance to design and construction requirements for the new hospital. When complete, the South Niagara Hospital will span 1.3M square feet on a 49.8-acre greenfield site. As an integral part of a connected healthcare system, the new facility will improve the patient and caregiver experience and strengthen access to local services.
STN Stantec $29.92 / -0.12 (-0.40%) 11/06/20 CIBC Stantec price target lowered to C$45 from C$49 at CIBC 11/06/20 Canaccord Stantec price target lowered to C$49 from C$51 at Canaccord 11/06/20 RBC Capital Stantec price target lowered to C$45 from C$47 at RBC Capital 11/06/20 BMO Capital Stantec price target lowered to C$41 from C$42 at BMO Capital

2020-11-24 06:53:15

STN

Stantec

$29.92 / -0.12 (-0.40%)

06:53

11/24/20

11/24

06:53

11/24/20

06:53

Stantec selected for PDS services for new South Niagara Hospital in Ontario

Global design firm, Stantec, was selected to provide planning, design, and conformance, or PDC, services for the new South Niagara Hospital in Niagara Falls, Ontario. Having previously completed the campus plan for Niagara Health, Stantec's healthcare team is now providing the illustrative schematic design, as well as detailed output specifications for the full range of design and construction requirements. Throughout the project duration, Stantec will evaluate conformance to design and construction requirements for the new hospital. When complete, the South Niagara Hospital will span 1.3M square feet on a 49.8-acre greenfield site. As an integral part of a connected healthcare system, the new facility will improve the patient and caregiver experience and strengthen access to local services.

STN Stantec

$29.92 / -0.12 (-0.40%)

11/06/20 CIBC: Stantec price target lowered to C$45 from C$49 at CIBC

11/06/20 Canaccord: Stantec price target lowered to C$49 from C$51 at Canaccord

11/06/20 RBC Capital: Stantec price target lowered to C$45 from C$47 at RBC Capital

11/06/20 BMO Capital: Stantec price target lowered to C$41 from C$42 at BMO Capital

TODAY'S FREE FLY STORIES

Periodicals	TSMC, UMC to see full capacity utilization for 28nm through Q3, DigiTimes says » 06:29 01/19/21 01/19 06:29 01/19/21 06:29 TSM TSMC $125.26 / -1.04 (-0.82%) , UMC UMC $8.79 / -0.715 (-7.52%) Both TSMC (TSM) and UMC… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options TSM UMC TSM TSMC $125.26 / -1.04 (-0.82%) 01/14/21 TSMC sees FY21 CapEx $25B-$28B 01/08/21 TSMC reports December revenue NT$117.37B, up 13.6% y/y 11/10/20 TSMC reports October revenue NT$119.3B, up 12.5% y/y 10/08/20 TSMC reports September revenue NT$127.59B, up 24.9% y/y UMC UMC $8.79 / -0.715 (-7.52%) 12/08/20 UMC reports November sales of NT$14.73M, up 6% 12/04/20 UMC rises 12.2% 12/04/20 UMC rises 10.6% 11/23/20 UMC rises 16.4% TSM UMC TSM TSMC $125.26 / -1.04 (-0.82%) 01/14/21 Needham Intel upgraded to Buy from Hold at Needham 01/12/21 Fly Intel: Top five analyst upgrades 01/12/21 Bernstein TSMC upgraded to Outperform from Market Perform at Bernstein 12/29/20 RBC Capital Intel intraday move on Third Point news looks 'overdone,' says RBC Capital UMC UMC $8.79 / -0.715 (-7.52%) 10/12/20 Credit Suisse UMC upgraded to Outperform from Neutral at Credit Suisse 09/14/20 HSBC UMC upgraded to Buy from Hold at HSBC 09/09/20 JPMorgan UMC upgraded to Neutral from Underweight at JPMorgan 08/02/20 Goldman Sachs UMC upgraded to Buy from Neutral at Goldman Sachs TSM TSM TSMC $125.26 / -1.04 (-0.82%) 01/14/21 TSMC sees Q1 revenue $12.7B-$13B, consensus $12.62B 01/14/21 TSMC reports Q4 EPS 97c, consensus 94c 10/15/20 TSMC sees Q4 revenue $12.4B-$12.7B, consensus $11.71B 10/15/20 TSMC reports Q3 EPS 90c, consensus 77c TSM TSM TSMC $125.26 / -1.04 (-0.82%) 01/14/21 TSMC pledges to fix global auto chip shortage, FT reports 01/12/21 Intel plans to outsource production of new chips to TSMC, Reuters reports 01/08/21 Intel has talked with TSMC, Samsung about outsourcing chips, Bloomberg reports 01/08/21 Intel has talked with TSMC, Samsung about outsourcing chips, Bloomberg reports TSM TSM TSMC $125.26 / -1.04 (-0.82%) 01/14/21 AMD slips as analyst says sell on Gelsinger's return to Intel 01/14/21 Fly Intel: Pre-market Movers 01/27/21 UMC - UMC TSM UMC TSM TSMC $125.26 / -1.04 (-0.82%) 12/15/20 Taiwan Semi call volume above normal and directionally bullish 12/11/20 Unusual call flow in option market yesterday 12/10/20 Call sale in Taiwan Semiconductor exits short-term trade for $3.2M loss 12/04/20 Taiwan Semi call volume above normal and directionally bullish UMC UMC $8.79 / -0.715 (-7.52%) 12/24/20 United Microelectronics call volume above normal and directionally bullish
Syndicate	ProPhase Labs 3M share Secondary priced at $12.50 » 06:28 01/19/21 01/19 06:28 01/19/21 06:28 PRPH ProPhase Labs $15.80 / +0.35 (+2.27%) ThinkEquity, a division… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings Events PRPH ProPhase Labs $15.80 / +0.35 (+2.27%) 12/08/20 ProPhase Labs expands COVID testing capacity with location in Garden City ,NY 11/02/20 ProPhase Labs completes acquisition of CLIA accredited lab 10/23/20 ProPhase Labs to acquire CLIA accredited laboratory for $2.5M 09/30/20 ProPhase to explore CLIA lab acquisition, enters agreement with Predictive Labs PRPH ProPhase Labs $15.80 / +0.35 (+2.27%) 08/11/20 ProPhase Labs reports Q2 EPS 1c vs. (11c) last year 00:00 Today 17th Annual Small & Microcap Virtual Investor Conference
Syndicate	TCR2 Therapeutics files to sell $125M in common stock » 06:27 01/19/21 01/19 06:27 01/19/21 06:27 TCRR TCR2 Therapeutics $32.87 / -0.93 (-2.75%) Goldman Sachs & Co.… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate TCRR TCR2 Therapeutics $32.87 / -0.93 (-2.75%) 01/08/21 TCR2 Therapeutics announces 2021 strategic priorities, milestones 12/13/20 TCR2 announces interim data from ongoing Phase 1 of TC-210 Phase 1/2 trial 12/11/20 TCR2 Therapeutics to announce TC-210 interim data 11/10/20 TCR2 Therapeutics partners with ElevateBio to expand TC-210 capacity TCRR TCR2 Therapeutics $32.87 / -0.93 (-2.75%) 12/22/20 Mizuho Autolus, Arcus among top 2021 oncology picks at Mizuho 12/15/20 Mizuho TCR2 Therapeutics price target raised to $58 from $33 at Mizuho 12/14/20 Piper Sandler TCR2 Therapeutics price target raised to $45 from $35 at Piper Sandler 12/14/20 BMO Capital TCR2 Therapeutics price target raised to $65 from $46 at BMO Capital TCRR TCR2 Therapeutics $32.87 / -0.93 (-2.75%) 11/12/20 TCR2 Therapeutics reports Q3 EPS (56c), consensus (53c) 08/12/20 TCR2 Therapeutics reports Q2 EPS (67c), consensus (64c) 29 Jul
Downgrade	Acadia Realty Trust downgraded to Neutral from Buy at BofA » 06:27 01/19/21 01/19 06:27 01/19/21 06:27 AKR Acadia Realty Trust $15.69 / -0.07 (-0.44%) BofA analyst Craig… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings AKR Acadia Realty Trust $15.69 / -0.07 (-0.44%) 06:10 Today BofA Acadia Realty Trust downgraded to Neutral from Buy at BofA 01/13/21 Jefferies Jefferies upgrades 'overlooked' Acadia Realty Trust to Buy 01/13/21 Jefferies Acadia Realty Trust upgraded to Buy from Hold at Jefferies 12/30/20 Truist Acadia Realty Trust price target raised to $15 from $12 at Truist AKR Acadia Realty Trust $15.69 / -0.07 (-0.44%) 11/03/20 Acadia Realty Trust reports Q3 FFO ex-items 20c, consensus 23c 08/05/20 Acadia Realty Trust reports Q2 adjusted FFO 29c, consensus 31c
Upgrade	Alsea upgraded to Overweight from Equal Weight at Barclays » 06:27 01/19/21 01/19 06:27 01/19/21 06:27 ALSSF Alsea $0.00 / + (+0.00%) Barclays analyst Benjamin… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 8 minutes Get Free Trial ShowHide Related Items >><< Street Research ALSSF Alsea $0.00 / + (+0.00%) 11/02/20 Scotiabank Alsea downgraded to Sector Perform from Outperform at Scotiabank 09/09/20 BBVA Alsea upgraded to Outperform from Underperform at BBVA 06/26/20 Morgan Stanley Alsea upgraded to Overweight from Equal Weight at Morgan Stanley

Periodicals	Tesla asks NHTSA to declare display issue 'inconsequential,' Reuters reports » 06:25 01/19/21 01/19 06:25 01/19/21 06:25 TSLA Tesla $826.55 / -17.94 (-2.12%) Tesla on Friday filed a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TSLA Tesla $826.55 / -17.94 (-2.12%) 01/14/21 Tesla director sells 10K shares of common stock 01/14/21 DPW Holdings subsidiary announces acceptance of pre-orders for EV charger 01/13/21 Tesla Model Y achieves 5-Star overall safety rating from NHTSA 01/11/21 Tesla's Andy Hamilton leaves car maker to join Redwood Materials TSLA Tesla $826.55 / -17.94 (-2.12%) 01/15/21 Wedbush Tesla price target raised to $950 from $715 at Wedbush 01/13/21 Fly Intel: Top five analyst initiations 01/13/21 Edward Jones Edward Jones starts Tesla at Hold, sees leadership balanced by competition 01/13/21 Edward Jones Tesla initiated with a Hold at Edward Jones TSLA Tesla $826.55 / -17.94 (-2.12%) 10/21/20 Tesla reports Q3 non-GAAP EPS 76c, consensus 56c 10/21/20 Notable companies reporting after market close 07/22/20 Tesla reports Q2 adjusted EPS 50c, consensus (11c) 07/22/20 Notable companies reporting after market close 14 Feb TSLA Tesla $826.55 / -17.94 (-2.12%) 01/18/21 Tesla says Model Y deliveries in China have officially begun 01/13/21 NHTSA asks Tesla to recall 158,000 cars over faulty touchscreens, Reuters says 01/10/21 Tesla hunts for design chief to create vehicles for China, Reuters reports 01/07/21 Apple self-driving EV at least half a decade away, Bloomberg reports TSLA Tesla $826.55 / -17.94 (-2.12%) 01/14/21 Fly Intel: Pre-market Movers 01/11/21 NIO jumps after unveiling new luxury sedan to rival Tesla 01/08/21 Fly Intel: Pre-market Movers 01/06/21 Fly Intel: Pre-market Movers 01/27/21 Tesla - TSLA TSLA Tesla $826.55 / -17.94 (-2.12%) 01/13/21 Notable open interest changes for January 13th 01/12/21 Notable open interest changes for January 12th 01/11/21 Notable open interest changes for January 11th 01/08/21 Notable open interest changes for January 8th
Recommendations	Turning Point Therapeutics price target raised to $190 from $130 at H.C. Wainwright » 06:25 01/19/21 01/19 06:25 01/19/21 06:25 TPTX Turning Point Therapeutics $131.57 / -6.23 (-4.52%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate TPTX Turning Point Therapeutics $131.57 / -6.23 (-4.52%) 01/11/21 Turning Point Therapeutics expects cash to fund operations into 2024 01/11/21 Turning Point Therapeutics announces 2021 milestone targets 01/11/21 Turning Point Therapeutics, Zai Lab expand collaboration to include TPX-0022 12/08/20 Turning Point granted breakthrough therapy designation for repotrectinib TPTX Turning Point Therapeutics $131.57 / -6.23 (-4.52%) 01/12/21 Oppenheimer Turning Point Therapeutics price target raised to $150 from $130 at Oppenheimer 01/12/21 JMP Securities Turning Point Therapeutics price target raised to $160 from $125 at JMP Securities 01/12/21 Oppenheimer Turning Point Therapeutics price target raised to $150 from $130 at Oppenheimer 12/14/20 SVB Leerink Turning Point Therapeutics price target raised to $127 from $116 at SVB Leerink TPTX Turning Point Therapeutics $131.57 / -6.23 (-4.52%) 08/10/20 Turning Point Therapeutics reports Q2 EPS (82c), consensus (89c) 27 Oct 19 May
Recommendations	IGM Biosciences price target raised to $114 from $88 at H.C. Wainwright » 06:24 01/19/21 01/19 06:24 01/19/21 06:24 IGMS IGM Biosciences $97.37 / +2.365 (+2.49%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals Options IGMS IGM Biosciences $97.37 / +2.365 (+2.49%) 01/11/21 IGM Biosciences enters exclusive licensing agreement with Medivir for birinapant 12/06/20 IGM Biosciences presents first clinical data from IGM-2323 in NHL 11/05/20 IGM Biosciences sees 2020 non-GAAP operating expenses $80M-$85M 11/04/20 IGM Biosciences to present data from IGM-2323 in NHL IGMS IGM Biosciences $97.37 / +2.365 (+2.49%) 12/22/20 Fly Intel: Top five analyst downgrades 12/22/20 Wedbush IGM Biosciences downgraded to Neutral at Wedbush 12/22/20 Wedbush IGM Biosciences downgraded to Neutral from Outperform at Wedbush 12/06/20 Piper Sandler IGM Biosciences price target raised to $89 from $81 at Piper Sandler IGMS IGM Biosciences $97.37 / +2.365 (+2.49%) 11/05/20 IGM Biosciences reports Q3 EPS (66c), consenus (69c) 08/06/20 IGM Biosciences reports Q2 EPS (62c), consensus (64c) 09 Dec IGMS IGM Biosciences $97.37 / +2.365 (+2.49%) 10/21/20 IGM Biosciences called 'next big bigtech collapse' by short-seller IGMS IGM Biosciences $97.37 / +2.365 (+2.49%) 08/12/20 Ten new option listings on August 12th
Upgrade	Brixmor upgraded to Buy from Neutral at BofA » 06:24 01/19/21 01/19 06:24 01/19/21 06:24 BRX Brixmor $16.86 / -0.025 (-0.15%) BofA analyst Craig… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events BRX Brixmor $16.86 / -0.025 (-0.15%) 11/18/20 Collection Sites enters agreement with Brixmor to launch testing sites BRX Brixmor $16.86 / -0.025 (-0.15%) 06:11 Today BofA Brixmor upgraded to Buy from Neutral at BofA 12/30/20 Truist Brixmor price target raised to $17 from $13 at Truist 12/10/20 Wells Fargo Brixmor downgraded to Equal Weight at Wells Fargo 12/10/20 Wells Fargo Brixmor downgraded to Equal Weight from Overweight at Wells Fargo BRX Brixmor $16.86 / -0.025 (-0.15%) 11/04/20 Brixmor reports Q3 FFO 36c, consensus 40c 08/03/20 Brixmor reports Q2 NAREIT FFO 32c, consensus 35c 02/12/21 Brixmor - BRX
Hot Stocks	SPI Energy subsidiary, Icona announce collaboration for all-electric vehicles » 06:24 01/19/21 01/19 06:24 01/19/21 06:24 SPI SPI Energy $34.00 / +12 (+1.00%) SPI Energy subsidiary… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Syndicate On The Fly Options SPI SPI Energy $34.00 / +12 (+1.00%) 01/12/21 SPI Energy provides FY20 business update 01/06/21 SPI Energy subsidiary acquires consumer contracts of Petersen-Dean 12/01/20 SPI Energy announces Phoenix Motorcars delivery of two Z500 utility trucks 11/13/20 SPI Energy acquires Phoenix Motorcars for $11.5M in stock, $1M in cash 01 Oct SPI SPI Energy $34.00 / +12 (+1.00%) 01/12/21 Fly Intel: Pre-market Movers 10/27/20 Fly Intel: Pre-market Movers SPI SPI Energy $34.00 / +12 (+1.00%) 12/28/20 SPI Energy call volume above normal and directionally bullish 12/15/20 Largest borrow rate increases among liquid names 11/10/20 Largest borrow rate increases among liquid names 11/09/20 Largest borrow rate increases among liquid names

Recommendations	SpringsWorks price target raised to $101 from $87 at H.C. Wainwright » 06:24 01/19/21 01/19 06:24 01/19/21 06:24 SWTX SpringsWorks Therapeutics $79.90 / +5.665 (+7.63%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate SWTX SpringsWorks Therapeutics $79.90 / +5.665 (+7.63%) 12/15/20 SpringsWorks Therapeutics promotes Badreddin Edris to COO 11/04/20 Allogene expects IND to be submitted by year-end on ALLO-715 w/ nirogacestat 10/26/20 Jazz Pharmaceuticals acquires SpringWorks Therapeutics' FAAH inhibitor program 10/05/20 SpringsWorks Therapeutics, Pfizer announce clinical trial collaboration SWTX SpringsWorks Therapeutics $79.90 / +5.665 (+7.63%) 12/28/20 H.C. Wainwright SpringsWorks Therapeutics price target raised to $87 from $73 at H.C. Wainwright 12/17/20 JPMorgan SpringsWorks Therapeutics price target raised to $85 from $57 at JPMorgan 12/17/20 Barclays SpringsWorks Therapeutics price target raised to $83 from $70 at Barclays 10/29/20 H.C. Wainwright SpringsWorks Therapeutics price target raised to $73 from $58 at H.C. Wainwright SWTX SpringsWorks Therapeutics $79.90 / +5.665 (+7.63%) 11/12/20 SpringsWorks Therapeutics reports Q3 EPS (51c), consensus (48c) 08/12/20 SpringsWorks Therapeutics reports Q2 EPS (47c), consensus (36c) 08 Oct
Earnings	Citrix sees FY21 adjusted EPS $6.20-$6.40, consensus $6.37 » 06:23 01/19/21 01/19 06:23 01/19/21 06:23 CTXS Citrix $132.09 / +0.07 (+0.05%) Sees FY21 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options CTXS Citrix $132.09 / +0.07 (+0.05%) 06:08 Today Citrix raises quarterly dividend to 37c from 35c per share 06:05 Today Citrix to acquire Wrike for $2.25B in cash 06:01 Today Citrix to acquire Wrike for $2.25B in cash 10/20/20 Citrix and Upwork expand collaboration in flexible work models, talent access CTXS Citrix $132.09 / +0.07 (+0.05%) 10/23/20 Morgan Stanley Citrix downgraded to Equal Weight on slower cloud progress at Morgan Stanley 10/23/20 RBC Capital Citrix price target lowered to $145 from $162 at RBC Capital 10/23/20 Citi Citrix price target raised to $205 from $195 at Citi 10/23/20 Morgan Stanley Citrix downgraded to Equal Weight from Overweight at Morgan Stanley CTXS Citrix $132.09 / +0.07 (+0.05%) 06:22 Today Citrix sees Q1 adjusted EPS $1.40-$1.45, consensus $1.47 06:07 Today Citrix reports Q4 adjusted EPS $1.46, consensus $1.33 10/22/20 Citrix sees FY21 EPS 6.20-$6.40, consensus $6.19 10/22/20 Citrix raises FY20 EPS $5.89-$5.99 from $5.65-$5.85, consensus 01/21/21 Citrix - CTXS CTXS Citrix $132.09 / +0.07 (+0.05%) 07/20/20 Early notable gainers among liquid option names on July 20th
Recommendations	Xoma price target raised to $56 from $30 at H.C. Wainwright » 06:23 01/19/21 01/19 06:23 01/19/21 06:23 XOMA Xoma $39.71 / + (+0.00%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings XOMA Xoma $39.71 / + (+0.00%) 11/16/20 Xoma earns $2M milestone from Takeda Pharmaceutical 11/11/20 Xoma earns $1M milestone payment from 2018 royalty purchase agreement 11/03/20 Xoma acquires royalty interest in four lysosomal storage disorder enzymes 10/28/20 Xoma earns $25M milestone payment as NIS793 enters Phase 2 study XOMA Xoma $39.71 / + (+0.00%) 03/10/20 H.C. Wainwright Novartis' recent R&D day driving interest in Xoma, says H.C. Wainwright XOMA Xoma $39.71 / + (+0.00%) 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 08/06/20 Xoma reports Q2 EPS (33c), consensus (38c)
Downgrade	Pandora A/S downgraded to Hold from Buy at HSBC » 06:23 01/19/21 01/19 06:23 01/19/21 06:23 PANDY Pandora A/S $0.00 / + (+0.00%) HSBC analyst Anne-Laure… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings PANDY Pandora A/S $0.00 / + (+0.00%) 12/08/20 Danske Bank Pandora A/S downgraded to Hold from Buy at Danske Bank 11/25/20 BofA Pandora A/S upgraded to Buy from Neutral at BofA 11/10/20 Morgan Stanley Pandora A/S price target raised to DKK 560 from DKK 360 at Morgan Stanley 11/04/20 Danske Bank Pandora A/S upgraded to Buy from Hold at Danske Bank PANDY Pandora A/S $0.00 / + (+0.00%) 08/17/20 Pandora A/S sees 2020 organic growth down 14% to down 20% 08/17/20 Pandora A/S reports Q2 organic growth down 38% vs. down 7% last year
Earnings	Citrix sees Q1 adjusted EPS $1.40-$1.45, consensus $1.47 » 06:22 01/19/21 01/19 06:22 01/19/21 06:22 CTXS Citrix $132.09 / +0.07 (+0.05%) Sees Q1 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 8 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options CTXS Citrix $132.09 / +0.07 (+0.05%) 06:08 Today Citrix raises quarterly dividend to 37c from 35c per share 06:05 Today Citrix to acquire Wrike for $2.25B in cash 06:01 Today Citrix to acquire Wrike for $2.25B in cash 10/20/20 Citrix and Upwork expand collaboration in flexible work models, talent access CTXS Citrix $132.09 / +0.07 (+0.05%) 10/23/20 Morgan Stanley Citrix downgraded to Equal Weight on slower cloud progress at Morgan Stanley 10/23/20 RBC Capital Citrix price target lowered to $145 from $162 at RBC Capital 10/23/20 Citi Citrix price target raised to $205 from $195 at Citi 10/23/20 Morgan Stanley Citrix downgraded to Equal Weight from Overweight at Morgan Stanley CTXS Citrix $132.09 / +0.07 (+0.05%) 06:07 Today Citrix reports Q4 adjusted EPS $1.46, consensus $1.33 10/22/20 Citrix sees FY21 EPS 6.20-$6.40, consensus $6.19 10/22/20 Citrix raises FY20 EPS $5.89-$5.99 from $5.65-$5.85, consensus 10/22/20 Citrix sees Q4 EPS $1.25-$1.35, consensus $1.31 01/21/21 Citrix - CTXS CTXS Citrix $132.09 / +0.07 (+0.05%) 07/20/20 Early notable gainers among liquid option names on July 20th

Recommendations	Biohaven price target lowered to $111 from $121 at H.C. Wainwright » 06:22 01/19/21 01/19 06:22 01/19/21 06:22 BHVN Biohaven Pharmaceutical $84.76 / -7.065 (-7.69%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate BHVN Biohaven Pharmaceutical $84.76 / -7.065 (-7.69%) 01/18/21 Biohaven's troriluzole did not differentiate from placebo in Alzheimer's trial 01/07/21 Biohaven Pharmaceutical acquires Kleo Pharmaceuticals, forms Biohaven Labs 01/04/21 Biohaven Pharmaceutical starts Phase 3 Trial of troriluzole in OCD 12/16/20 Biohaven's rimegepant shows efficacy and safety for migraine in Phase 3 trial BHVN Biohaven Pharmaceutical $84.76 / -7.065 (-7.69%) 04:54 Today Piper Sandler Biohaven should pull back to mid-$70's on Alzheimer's miss, says Piper Sandler 12/29/20 Cantor Fitzgerald Biohaven price target raised to $115 from $109 at Cantor Fitzgerald 12/23/20 Piper Sandler Piper 'comfortable' owning Biohaven shares into Alzheimer's readout 12/15/20 H.C. Wainwright Biohaven Pharmaceutical initiated with a Buy at H.C. Wainwright BHVN Biohaven Pharmaceutical $84.76 / -7.065 (-7.69%) 11/09/20 Biohaven Pharmaceutical reports Q3 adj. EPS ($2.67), consensus ($2.89) 08/10/20 Biohaven Pharmaceutical reports Q2 non-GAAP EPS ($2.55), consensus ($2.61) 29 Jan
Initiation	Airbnb initiated with a Sell at Redburn » 06:22 01/19/21 01/19 06:22 01/19/21 06:22 ABNB ABNB / + Redburn initiated… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate Periodicals On The Fly Options ABNB ABNB / + 01/13/21 Airbnb to cancel reservations in D.C. area during Inauguration week 01/11/21 Airbnb says its PAC will 'withhold support' from those who opposed certification 01/10/21 Fly Intel: Top five weekend stock stories 12/23/20 IBM, Airbnb announce settlement in patent litigation ABNB ABNB / + 01/14/21 Truist Airbnb initiated with a Hold at Truist 01/08/21 Tigress Financial Airbnb initiated with a Buy at Tigress Financial 01/05/21 William Blair Blair starts Airbnb with Outperform on 'strong' consumer awareness 01/05/21 Citi Airbnb initiated with a Neutral at Citi 10 Dec ABNB ABNB / + 01/14/21 Airbnb CEO says travel will permanently change due to pandemic, Reuters says 01/10/21 Airbnb Section 230 use underscores law's reach beyond Facebook, WSJ says 12/24/20 Airbnb asked by California counties to halt Lake Tahoe rentals, SFC reports 12/09/20 Airbnb to price IPO at $68 per share, above $56-$60 target range, Bloomberg says ABNB ABNB / + 01/04/21 Airbnb under pressure as Wall Street analysts roll out coverage following IPO 12/14/20 Fly Intel: Pre-market Movers ABNB ABNB / + 01/14/21 Airbnb call volume above normal and directionally bullish 01/13/21 Option volume wakes up in AirBnB as shares lift 5% 01/12/21 Airbnb call volume above normal and directionally bullish 12/16/20 Eight new option listings and one option delisting on December 16th
Upgrade	WWE upgraded to Outperform from In Line at Evercore ISI » 06:21 01/19/21 01/19 06:21 01/19/21 06:21 WWE WWE $37.00 / +12 (+5.00%) Evercore ISI analyst John… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events WWE WWE $37.00 / +12 (+5.00%) 11/25/20 WWE names Karen Mullane as Controller & Chief Accounting Officer 11/20/20 WWE, Credit One Bank enter multi-year partnership 09/22/20 WWE director sells 57.6K shares of common stock 09/21/20 iQIYI announces partnership with WWE WWE WWE $37.00 / +12 (+5.00%) 01/11/21 Fly Intel: Top five analyst initiations 01/11/21 Barclays WWE initiated with an Equal Weight at Barclays 10/27/20 Morgan Stanley WWE price target lowered to $47 from $52 at Morgan Stanley 10/06/20 MKM Partners WWE price target lowered to $50 from $58 at MKM Partners WWE WWE $37.00 / +12 (+5.00%) 10/29/20 WWE reports Q3 adjusted EPS 56c, consensus 38c 07/30/20 WWE reports Q2 adjusted EPS 45c, consensus 14c 25 Mar WWE WWE $37.00 / +12 (+5.00%) 11/20/20 WWE agrees to multi-year partnership deal with Credit One, Sportico reports WWE WWE $37.00 / +12 (+5.00%) 07/30/20 Fly Intel: After-Hours Movers 02/04/21 WWE - WWE
Upgrade	WWE upgraded to Outperform from In Line at Evercore ISI » 06:21 01/19/21 01/19 06:21 01/19/21 06:21 WWE WWE $50.86 / -0.89 (-1.72%) Evercore ISI analyst John… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events WWE WWE $50.86 / -0.89 (-1.72%) 11/25/20 WWE names Karen Mullane as Controller & Chief Accounting Officer 11/20/20 WWE, Credit One Bank enter multi-year partnership 09/22/20 WWE director sells 57.6K shares of common stock 09/21/20 iQIYI announces partnership with WWE WWE WWE $50.86 / -0.89 (-1.72%) 01/11/21 Fly Intel: Top five analyst initiations 01/11/21 Barclays WWE initiated with an Equal Weight at Barclays 10/27/20 Morgan Stanley WWE price target lowered to $47 from $52 at Morgan Stanley 10/06/20 MKM Partners WWE price target lowered to $50 from $58 at MKM Partners WWE WWE $50.86 / -0.89 (-1.72%) 10/29/20 WWE reports Q3 adjusted EPS 56c, consensus 38c 07/30/20 WWE reports Q2 adjusted EPS 45c, consensus 14c 25 Mar WWE WWE $50.86 / -0.89 (-1.72%) 11/20/20 WWE agrees to multi-year partnership deal with Credit One, Sportico reports WWE WWE $50.86 / -0.89 (-1.72%) 07/30/20 Fly Intel: After-Hours Movers 02/04/21 WWE - WWE
Downgrade	Live Nation downgraded to In Line from Outperform at Evercore ISI » 06:21 01/19/21 01/19 06:21 01/19/21 06:21 LYV Live Nation $71.52 / -1.83 (-2.49%) Evercore ISI analyst Josh… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options LYV Live Nation $71.52 / -1.83 (-2.49%) 09/16/20 Slack Technologies names Nadia Rawlinson as chief people officer 09/04/20 Live Nation announces Usher to headline Las Vegas residency at Caesars Palace LYV Live Nation $71.52 / -1.83 (-2.49%) 12/17/20 Morgan Stanley Live Nation price target raised to $70 from $56 at Morgan Stanley 11/30/20 Macquarie Live Nation downgraded to Neutral on valuation at Macquarie 11/30/20 Macquarie Live Nation downgraded to Neutral from Outperform at Macquarie 10/27/20 Jefferies Live Nation downgraded to Hold from Buy at Jefferies LYV Live Nation $71.52 / -1.83 (-2.49%) 11/05/20 Live Nation reports Q3 EPS ($2.45), consensus ($2.20) 11/05/20 Notable companies reporting after market close 08/05/20 Live Nation reports Q2 EPS ($2.67), consensus ($2.08) 08/05/20 Notable companies reporting after market close LYV Live Nation $71.52 / -1.83 (-2.49%) 01/04/21 Ticketmaster to pay $10M fine to resolve federal charges, WSJ reports 10/05/20 Ticketmaster Chairman Jared Smith stepping down at year-end, Variety reports 10/02/20 Live Nation's movie production arm lays off top exec, NY Post reports 08/20/20 DOJ antitrust chief Delrahim orders restructuring to focus enforcement, WSJ says LYV Live Nation $71.52 / -1.83 (-2.49%) 11/05/20 Fly Intel: After-Hours Movers LYV Live Nation $71.52 / -1.83 (-2.49%) 11/05/20 Live Nation put volume heavy and directionally bearish 09/14/20 Live Nation put volume heavy and directionally bearish 09/04/20 Live Nation put volume heavy and directionally bearish 09/03/20 Live Nation put volume heavy and directionally bearish

Upgrade	Retail Opportunity double-upgraded to Buy from Underperform at BofA » 06:21 01/19/21 01/19 06:21 01/19/21 06:21 ROIC Retail Opportunity $14.31 / -0.085 (-0.59%) BofA analyst Craig… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Earnings Events ROIC Retail Opportunity $14.31 / -0.085 (-0.59%) 06:11 Today BofA Retail Opportunity upgraded to Buy from Underperform at BofA 12/14/20 KeyBanc Retail Opportunity downgraded to Sector Weight from Overweight at KeyBanc 12/10/20 Wells Fargo Retail Opportunity downgraded to Underweight at Wells Fargo 12/10/20 Wells Fargo Retail Opportunity downgraded to Underweight from Equal Weight at Wells Fargo ROIC Retail Opportunity $14.31 / -0.085 (-0.59%) 10/26/20 Retail Opportunity reports Q3 FFO 25c, consensus 23c 07/29/20 Retail Opportunity reports Q2 EPS 4c, consensus 2c 02/24/21 Retail Opportunity - ROIC
Recommendations	Acceleron price target raised to $168 from $148 at H.C. Wainwright » 06:21 01/19/21 01/19 06:21 01/19/21 06:21 XLRN Acceleron $126.32 / -0.7 (-0.55%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate XLRN Acceleron $126.32 / -0.7 (-0.55%) 12/14/20 EC grants orphan designation to Acceleron's sotatercept for PAH treatment 12/01/20 Acceleron gets FDA orphan drug designation for ACE-1334 11/13/20 Acceleron presents new data from PULSAR Phase 2 trial at AHA meeting 09/29/20 Acceleron, Bristol-Myers announce Health Canada approval of REBLOZYL XLRN Acceleron $126.32 / -0.7 (-0.55%) 12/21/20 Barclays Acceleron price target raised to $150 from $133 at Barclays 11/16/20 Oppenheimer Acceleron price target raised to $131 from $120 at Oppenheimer 11/06/20 H.C. Wainwright Acceleron price target raised to $148 from $137 at H.C. Wainwright 10/02/20 Piper Sandler Piper says Acceleron STELLAR trial design details generally as expected XLRN Acceleron $126.32 / -0.7 (-0.55%) 11/05/20 Acceleron reports Q3 EPS (66c), consensus (61c) 11/05/20 Acceleron says Reblozy Q3 revenue $96M 08/06/20 Acceleron reports Q2 EPS (34c), consensus (57c) 01 Jul
Recommendations	TG Therapeutics price target raised to $78 from $61 at H.C. Wainwright » 06:19 01/19/21 01/19 06:19 01/19/21 06:19 TGTX TG Therapeutics $49.56 / -1.64 (-3.20%) H.C. Wainwright analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options TGTX TG Therapeutics $49.56 / -1.64 (-3.20%) 12/10/20 TG Therapeutics says ULTIMATE I, II Phase 3 studies met primary endpoint 12/07/20 TG Therapeutics announces data from UNITY-CLL, UNITY-NHL trials 12/02/20 TG Therapeutics announces publication of Phase 2 umbralisib data 12/01/20 TG Therapeutics initiates rolling submission of BLA for ublituximab/umbralisib TGTX TG Therapeutics $49.56 / -1.64 (-3.20%) 12/10/20 H.C. Wainwright TG Therapeutics price target raised to $61 from $38 at H.C. Wainwright 12/10/20 Evercore ISI TG Therapeutics price target raised to $70 from $65 at Evercore ISI 10/28/20 Cantor Fitzgerald TG Therapeutics price target raised to $48 from $30 at Cantor Fitzgerald 10/09/20 B. Riley Securities TG Therapeutics price target raised to $52 from $37 at B. Riley Securities TGTX TG Therapeutics $49.56 / -1.64 (-3.20%) 11/09/20 TG Therapeutics reports Q EPS (73c), consensus (41c) 08/10/20 TG Therapeutics reports Q2 EPS (47c), consensus (34c) 15 Dec 15 May TGTX TG Therapeutics $49.56 / -1.64 (-3.20%) 08/10/20 Fly Intel: Pre-market Movers 02/15/21 PDUFA Date for Umbralisib 06/15/21 PDUFA Date for Umbralisib (FL Indication--Standard Review) TGTX TG Therapeutics $49.56 / -1.64 (-3.20%) 12/11/20 TG Therapeutics call volume above normal and directionally bullish
Upgrade	Bryn Mawr Bank upgraded to Overweight from Equal Weight at Stephens » 06:19 01/19/21 01/19 06:19 01/19/21 06:19 BMTC Bryn Mawr Bank $33.77 / +0.07 (+0.21%) Stephens analyst Matt… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings Events BMTC Bryn Mawr Bank $33.77 / +0.07 (+0.21%) 12/16/20 Boenning & Scattergood Bryn Mawr Bank upgraded to Outperform from Neutral at Boenning & Scattergood 06/01/20 Stephens Bryn Mawr Bank initiated with an Equal Weight at Stephens 04/01/20 Keefe Bruyette Bryn Mawr Bank upgraded to Outperform from Market Perform at Keefe Bruyette BMTC Bryn Mawr Bank $33.77 / +0.07 (+0.21%) 10/22/20 Bryn Mawr Bank reports Q3 core EPS 77c, consensus 61c 07/20/20 Bryn Mawr Bank reports Q2 core EPS 77c, consensus 51c 01/22/21 Bryn Mawr Bank - BMTC
Recommendations	SunPower price target raised to $35 from $22 at Piper Sandler » 06:18 01/19/21 01/19 06:18 01/19/21 06:18 SPWR SunPower $31.97 / -3.1 (-8.84%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 8 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SPWR SunPower $31.97 / -3.1 (-8.84%) 01/07/21 SunPower closing manufacturing facility in Hillsboro, Oregon 01/07/21 Hannon Armstrong announces leadership moves, promotes Jeffrey Lipson to COO 08/27/20 Total 'fully supports' SunPower spin-off of Maxeon Solar 08/27/20 SunPower, Maxeon Solar complete spin-off transaction SPWR SunPower $31.97 / -3.1 (-8.84%) 01/12/21 Fly Intel: Top five analyst initiations 01/12/21 Truist SunPower initiated with a Hold at Truist 01/12/21 Truist SunPower initiated with a Hold at Truist 01/04/21 Goldman Sachs SunPower price target raised to $33 from $23 at Goldman Sachs SPWR SunPower $31.97 / -3.1 (-8.84%) 10/28/20 SunPower raises 2020 non-GAAP revenue view to $1.12-$1.16B from $1.06B-$1.10B 10/28/20 SunPower still sees Q4 revenue $330M-$370M, consensus $350.28M 10/28/20 SunPower reports Q3 non-GAAP EPS (4c), consensus (5c) 10/28/20 Notable companies reporting after market close SPWR SunPower $31.97 / -3.1 (-8.84%) 11/11/20 Former Google exec seen as 'top' Biden energy pick, Bloomberg reports SPWR SunPower $31.97 / -3.1 (-8.84%) 10/28/20 Fly Intel: After-Hours Movers 10/27/20 Fly Intel: Pre-market Movers 10/26/20 Street Fight: Roth says buy First Solar, Credit Suisse says sell 03/15/21 33rd Annual Roth Virtual Conference SPWR SunPower $31.97 / -3.1 (-8.84%) 01/14/21 SunPower call volume above normal and directionally bullish 11/04/20 Unusually active option classes on open November 4th 11/03/20 SunPower put volume heavy and directionally bearish 10/20/20 SunPower call volume above normal and directionally bullish

Events

Earnings calls, analyst events, roadshows and more

CMA
Today at 08:00

Comerica - CMA Conference Calls
PETS
Today at 08:00

PetMed Express - PETS Conference Calls
BAC
Today at 08:30

Bank of America - BAC Conference Calls
LOGI
Today at 08:30

Logitech - LOGI Conference Calls
HAL
Today at 09:00

Halliburton - HAL Conference Calls
EPAC
Today at 09:00

Enerpac Tool Group Corp Firm Sponsored Meetings

N86 W12500 Westbrook Crossing, Menomonee Falls, WI
OACB
Today at 09:00

OAKTREE ACQUISITION CORP. II Firm Sponsored Meetings

New York, NY
Today at 09:00

Healthcare Industry Meetings
GS
Today at 09:30

Goldman Sachs - GS Conference Calls
Today at 10:00

Board of Directors Meeting Government Event

Virtual Meeting

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	DFH X DFH Dream Finders Homes IPO Managers: BofA, RBC Capital & BTIG, Builder Advisor, Zelman, TCB Capital, Wedbush $12.00-15.00 9.6M Shares MYTE X MYTE Mytheresa IPO Managers: Morgan Stanley & JPMorgan, Credit Suisse, UBS, Jefferies, Cowen $16.00-18.00 15.647M Shares
Thurs	PAX X PAX Patria IPO Managers: JPMorgan, BofA & Credit Suisse, Goldman Sachs, Bradesco BBI, BTG Pactual, ITAU, Keefe Bruyette, Santander, XP $14.00-16.00 26.65M Shares
Fri	No deals

View All Syndicate Announcements »

Stantec selected for PDS services for new South Niagara Hospital in Ontario

TODAY'S FREE FLY STORIES

Get Full Fly Access